Schizophrenia News and Research

Latest Schizophrenia News and Research

Project Spark to advance neuroprotective drug for schizophrenia-associated cognitive impairment

A public-private consortium led by the biotech Iproteos -based at Parc Científic de Barcelona (PCB)-, and comprised by the biopharmaceutical company Ascil-Biopharma, the Institute for Biomedical Research (IRB Barcelona), the Centre for Genomic Regulation (CRG) and the University of the Basque Country (UPV/EHU) has launched a project to advance the development of a new neuroprotective drug for the treatment of the cognitive impairment associated with schizophrenia and other mental disorders.

31 Jan 2015

Study helps develop better understanding of how dopamine influences behaviour

Scientists studying hatchling fish have made a new advance in studying a chemical in the brain that impacts on movement.

29 Jan 2015

People who carry longevity gene variant have larger brain region

People who carry a variant of a gene that is associated with longevity also have larger volumes in a front part of the brain involved in planning and decision-making, according to researchers at UC San Francisco.

29 Jan 2015

ADDF awards grant to support initiation of AGB101 Phase 3 trial for aMCI treatment

The Alzheimer's Drug Discovery Foundation announced today a $900,000 grant to AgeneBio, a pharmaceutical company developing innovative therapies for neurologic and psychiatric diseases. The grant will support the initiation of an FDA-registered Phase 3 clinical trial of AGB101, a new therapeutic treatment for amnestic mild cognitive impairment (aMCI).

28 Jan 2015

Heptares Therapeutics announces recipients of Malcolm Campbell Memorial Prize for 2015

Heptares Therapeutics, the clinical-stage GPCR structure-guided drug discovery and development company, is delighted to announce that the Malcolm Campbell Memorial Prize for 2015 has been awarded to Miles Congreve (Vice President of Chemistry), Fiona Marshall (Chief Scientific Officer and co-founder) and Malcolm Weir (Chief Executive Officer and co-founder) for the seminal contributions to GPCR drug discovery made by Heptares Therapeutics since the company was founded in 2007.

23 Jan 2015

International study identifies genetic factors that influence the size of brain structures

An international study, which included researchers from NUI Galway, has identified significant genetic factors that influence the size of structures within the brain. It is hoped these new insights may help scientists better understand disorders such as schizophrenia, Alzheimer's disease and epilepsy.

23 Jan 2015

Heptares Therapeutics, AstraZeneca report significant progress in drug discovery collaboration

Heptares Therapeutics, the clinical-stage GPCR structure-guided drug discovery and development company, announces significant progress in its drug discovery collaboration with AstraZeneca.

22 Jan 2015

Hallucinations linked to self-destructive thoughts among adolescents with psychological symptoms

Visual distortions and hallucinations related to an elevated risk of psychosis are linked to self-destructive thought processes among adolescents with psychological symptoms, according to a recent Finnish study. Early indications of the risk of psychosis can usually be detected long before the onset of a full-blown disorder.

22 Jan 2015

Personalized approaches to treating intellectual disability

Scientists from the Florida campus of The Scripps Research Institute have produced an approach that protects animal models against a type of genetic disruption that causes intellectual disability, including serious memory impairments and altered anxiety levels.

22 Jan 2015

Johnson & Johnson announces sales of $18.3 billion for Q4 2014

Johnson & Johnson today announced sales of $18.3 billion for the fourth quarter of 2014, a decrease of 0.6% as compared to the fourth quarter of 2013. Operational results increased 3.9% and the negative impact of currency was 4.5%. Domestic sales increased 7.4%.

20 Jan 2015

Researchers identify novel life-preserving circuit responsible for recognizing threats

Our existence depends on a bit of evolutionary genius aptly nicknamed "fight or flight." But where in our brain does the alarm first go off, and what other parts of the brain are mobilized to express fear and remember to avoid danger in the future?

20 Jan 2015

Gedeon Richter, Actavis report positive top line results from cariprazine Phase III trial

Gedeon Richter Plc. and Actavis plc today announced positive results from a Phase III trial evaluating the efficacy and safety of cariprazine in the prevention of relapse in patients with schizophrenia.

20 Jan 2015

Venom of cone snails provides leads for possible treatment of cancer, addiction

While considered a delicacy in some parts of the world, snails have found a more intriguing use to scientists and the medical profession offering a plethora of research possibilities. Cone snails are marine mollusks, just as conch, octopi and squid, but they capture their prey using venom.

15 Jan 2015

State and federal prisoners not receiving adequate mental health care

A significant portion of state and federal prisoners are not receiving treatment for mental health conditions, according to research by The University of Texas Health Science Center at Houston School of Public Health.

12 Jan 2015

Longitudinal course of schizophrenia negative symptoms revealed

Schizophrenia negative symptoms are relatively stable in the first year for most patients after they begin antipsychotic medication but research suggests around a quarter will experience exacerbation or relapse.

7 Jan 2015

Comorbid OCD not uncommon in bipolar disorder

Co-occurrence of obsessive compulsive disorder in patients with bipolar disorder type I is not uncommon and is associated with increased functional disability, research findings indicate.

7 Jan 2015

CET ‘feasible’ in schizophrenia patients with substance misuse

Patients with schizophrenia and comorbid substance abuse diagnoses are able to benefit from cognitive enhancement therapy, preliminary research suggests.

7 Jan 2015

McGill University researchers identify network of complex neurons in the brain

Our ability to pay attention to certain things while ignoring distractions determines how good we are at a given task, whether it is driving a car or doing brain surgery. A research team at McGill University has for the first time convincingly identified a network of neurons in a particular area of the brain, the lateral prefrontal cortex, that interact with one another to promptly filter visual information while at the same time ignoring distractions. It's a discovery with potentially far reaching implications for people who suffer from diseases such as autism, ADHD and schizophrenia.

7 Jan 2015

FDA receives Actavis' NDA resubmission for cariprazine

Actavis plc (NYSE: ACT) and Gedeon Richter Plc. today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of Actavis' New Drug Application (NDA) resubmission for its atypical antipsychotic cariprazine, a potent dopamine D3/D2 receptor partial agonist with preferential binding to D3 receptors.

6 Jan 2015

LIBD announces significant advances in identifying causes of schizophrenia, brain disorders

The Lieber Institute for Brain Development (LIBD) announces significant advances in identifying the causes of schizophrenia and related developmental brain disorders and translating these findings into new treatment strategies.

31 Dec 2014

Schizophrenia News and Research

Latest Schizophrenia News and Research

Project Spark to advance neuroprotective drug for schizophrenia-associated cognitive impairment

Study helps develop better understanding of how dopamine influences behaviour

People who carry longevity gene variant have larger brain region

ADDF awards grant to support initiation of AGB101 Phase 3 trial for aMCI treatment

Heptares Therapeutics announces recipients of Malcolm Campbell Memorial Prize for 2015

International study identifies genetic factors that influence the size of brain structures

Heptares Therapeutics, AstraZeneca report significant progress in drug discovery collaboration

Hallucinations linked to self-destructive thoughts among adolescents with psychological symptoms

Personalized approaches to treating intellectual disability

Johnson & Johnson announces sales of $18.3 billion for Q4 2014

Researchers identify novel life-preserving circuit responsible for recognizing threats

Gedeon Richter, Actavis report positive top line results from cariprazine Phase III trial

Venom of cone snails provides leads for possible treatment of cancer, addiction

State and federal prisoners not receiving adequate mental health care

Longitudinal course of schizophrenia negative symptoms revealed

Comorbid OCD not uncommon in bipolar disorder

CET ‘feasible’ in schizophrenia patients with substance misuse

McGill University researchers identify network of complex neurons in the brain

FDA receives Actavis' NDA resubmission for cariprazine

LIBD announces significant advances in identifying causes of schizophrenia, brain disorders

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Unlocking live single-cell functional insights

Schizophrenia News and Research

Latest Schizophrenia News and Research

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Unlocking live single-cell functional insights

Newsletters you may be interested in